Home » News » Drug Sponsors » MorphoSys completes sale of AbD Serotec to Bio-Rad

MorphoSys completes sale of AbD Serotec to Bio-Rad

Friday, January 11, 2013

MorphoSys, a biotechnology company focusing on fully human antibodies, has completed the sale of its research and diagnostic antibody segment AbD Serotec to Waltham, Mass.-based Bio-Rad Laboratories.

All assets and liabilities of the AbD Serotec segment of MorphoSys, as well as all shares of the subsidiaries MorphoSys U.K., MorphoSys AbD GmbH and MorphoSys U.S., have been transferred to Bio-Rad.

“We are delighted to have reached the closing of the transaction just a few weeks after the announcement was made. With the divestment of AbD Serotec completed, MorphoSys can devote 100% of its attention to building value in its core therapeutics business,” said Jens Holstein, CFO of MorphoSys.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!